Spending, utilization, and coverage for chronic rhinosinusitis with nasal polyposis therapies among Medicare Advantage beneficiaries

IF 7.2 2区医学 Q1 OTORHINOLARYNGOLOGY

International Forum of Allergy & Rhinology Pub Date : 2024-06-25 DOI:10.1002/alr.23362

Akash M. Bhat BS, Zachary M. Soler MD, MSc, Vinay K. Rathi MD, MBA, Rodney J. Schlosser MD

引用次数: 0

Abstract

Key points

CRSwNP-specific mean total annual spending ranged from $5,837 (EDS-FLU) to $28,058 (dupilumab).
Most CRSwNP patients receiving biologics had comorbid asthma and did not undergo sinus surgery.
While biologics were covered by most Medicare Part D plans, only 37% of plans covered EDS-FLU.

查看原文本刊更多论文

医疗保险优势受益人在慢性鼻炎伴鼻息肉治疗方面的支出、使用情况和保险范围。

要点：CRSwNP特异性年平均总支出从5837美元（EDS-FLU）到28058美元（dupilumab）不等。大多数接受生物制剂治疗的 CRSwNP 患者合并有哮喘，且未接受鼻窦手术。虽然大多数医疗保险 D 部分计划都涵盖了生物制剂，但只有 37% 的计划涵盖了 EDS-FLU。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Forum of Allergy & Rhinology OTORHINOLARYNGOLOGY-

CiteScore

11.70

自引率

10.90%

发文量

185

审稿时长

6-12 weeks

期刊介绍： International Forum of Allergy & Rhinologyis a peer-reviewed scientific journal, and the Official Journal of the American Rhinologic Society and the American Academy of Otolaryngic Allergy. International Forum of Allergy Rhinology provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions. The application of current research to the management of otolaryngic allergy, rhinologic, and skull base diseases and the need for further investigation will be highlighted.